Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;3(6):396-408.
doi: 10.1007/s40495-017-0112-3. Epub 2017 Oct 11.

Pancreatic cancer: Current status and Challenges

Affiliations

Pancreatic cancer: Current status and Challenges

Amanda R Muñoz et al. Curr Pharmacol Rep. 2017 Dec.

Abstract

Purpose of the review: The 5-year survival rate of patients with pancreatic cancer (PanCA) has remained stagnant. Unfortunately, the incidence is almost equal to mortality rates. These facts underscore the importance of concerted efforts to understand the pathology of this disease. Deregulation of multiple signaling pathways involved in a wide variety of cellular processes including proliferation, apoptosis, invasion, and metastasis contribute not only to cancer development but also to therapeutic resistance. The purpose of this review is to summarize current understanding of etiological factors including emerging evidence on the role of infectious agents, factors associated with therapeutic resistance and therapeutic options.

Recent findings: The unique aspect of PanCA is "desmoplasia", a process that involves proliferation of stromal fibroblasts and collagen deposition in and around the filtrating cancer. Recent studies have identified pancreatic stellate cells (PSCs) as a potential source of such desmoplasia. Biphasic interactions between PSCs and cancer cells, endothelial cells, and/or myeloid derived suppressor cells in the tumor microenvironment contribute to pancreatic carcinogenesis.

Summary: We summarize limitations of current therapeutic approaches and potential strategies to overcome these limitations using natural products including botanicals as adjuvant/neo-adjuvant for effective management of PanCA.

Keywords: Chemotherapy; Gemcitabine; Natural products; Pancreatic cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: Authors declare no conflicts of interest.

Similar articles

Cited by

References

    1. Ilic M, Ilic I. Epidemiology of pancreatic cancer. World Journal of Gastroenterology. 2016;22(44):9694–705. doi: 10.3748/wjg.v22.i44.9694. - DOI - PMC - PubMed
    1. Wong C-H, Li Y-J, Chen Y-C. Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancer. World journal of gastroenterology. 2016;22(31):7046. - PMC - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA: A Cancer Journal for Clinicians. 2017;67(1):7–30. doi: 10.3322/caac.21387. - DOI - PubMed
    1. Kamisawa T, Wood LD, Itoi T, Takaori K. Pancreatic cancer. The Lancet. 2016;388(10039):73–85. doi: 10.1016/s0140-6736(16)00141-0. - DOI - PubMed
    1. Ryan D, Hong T, Bardeesy N. Pancreatic Adenocarcinoma. N Engl J Med. 2014;371:1039–49. doi: 10.1056/NEJMra1404198. - DOI - PubMed

LinkOut - more resources